Abiocode Logo

Quantity: 100 ul                                                                                          Application: WB

Predicted I Observed M.W.: 24 I 29 kDa                                                  Uniprot ID: P40337

Background:

Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of the VHL gene is the basis of familial inheritance of VHL syndrome. VHL is a component of the protein complex that includes elongin B, elongin C and cullin-2, and possesses ubiquitin ligase E3 activity. VHL is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of VHL. Alternatively spliced transcript variants encoding distinct isoforms have been observed.

Other Names:

Von Hippel-Lindau disease tumor suppressor, Protein G7, pVHL, VHL1

Source and Purity:

Rabbit polyclonal antibodies were produced by immunizing animals with a GST-fusion protein containing the C-terminal region of human VHL. Antibodies were purified by affinity purification using immunogen. 

Storage Buffer and Condition:

Supplied in 1 x PBS (pH 7.4), 100 ug/ml BSA, 40% Glycerol, 0.01% NaN₃. Store at -20 °C. Stable for 6 months from date of receipt.

Species Specificity:

Human, Mouse

Tested Applications:

WB: 1:1,000-1:3,000 (detect endogenous protein*)

*: The apparent protein size on WB may be different from the calculated M.W. due to modifications.

Product Data: